Work

Cost-Effectiveness of Combination Amivantamab–Lazertinib, Osimertinib Plus Chemotherapy, and Osimertinib Monotherapy in Lung Cancer

Year: 2026

Type: article

Source: Journal of the National Comprehensive Cancer Network

DOI: 10.6004/jnccn.2026.7017

Authors: Jui-Hung Tsai, Sheng-Han Tsai, Li-Jun Chen, Szu-Chun Yang

Institutions: National Cheng Kung University Hospital, National Cheng Kung University

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7169076626

FWCI:

Cites:

Cited by:

Related to: